Drug intelligence / Profile preview

suyisu

Development stage: Unknown
Lead developer: Nestlé
Modality: Inhalation Devices → Device-based Delivery → Drug Delivery Systems, Implantable Devices → Device-based Delivery → Drug Delivery Systems, Transdermal Patches → Device-based Delivery → Drug Delivery Systems
Administration: Oral

Overview

Suyisu (速熠素) is a specialized medical nutrition product developed for individuals aged 10 and above with cancer. It is classified as a total nutrition formula food for special medical purposes, designed to provide comprehensive nutritional support during cancer treatment or recovery. The formulation includes added L-arginine, fish oil, and nucleotides to support immune function and overall health. Each 250 mL bottle provides approximately 354 kcal and contains about 21.5 grams of protein[1]. Suyisu is intended for oral administration as part of clinical nutrition therapy in oncology settings.

Brand names: 速熠素
Other names: Oral Impact (Chinese market)

Beyond the preview

Go deeper on suyisu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on suyisu.

Explore the full profile